MREO - Mereo BioPharma Group plc

NasdaqCM - NasdaqCM Real-time price. Currency in USD
1.2400
+0.0900 (+7.83%)
At close: 04:00PM EDT
1.2400 0.00 (0.00%)
Pre-market: 09:09AM EDT
Stock chart is not supported by your current browser
Previous close1.1500
Open1.1300
Bid1.2600 x 1000
Ask1.2500 x 1000
Day's range1.1350 - 1.3600
52-week range0.4950 - 1.8500
Volume5,674,006
Avg. volume1,837,503
Market cap154.983M
Beta (5Y monthly)0.83
PE ratio (TTM)N/A
EPS (TTM)-0.4000
Earnings date28 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • Globe Newswire

    Mereo BioPharma to Present at the Jefferies Healthcare Conference

    LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 09:30am ET / 01:30pm GMT. A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/inves

  • Globe Newswire

    Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

    LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), as well as post-hoc analyses demonstrating the association between biomarker reductions with alvelestat and improvements in SGRQ, a key Patient-Reported Outcome

  • Globe Newswire

    Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

    LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it received written confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that it had regained compliance with the minimum bid price requirement under the Nasdaq Listing Rules for continued Nasdaq listing, and is now compliant with applicable listing standards for continued Nasdaq listing. To reg

  • Globe Newswire

    Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

    LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on May 3, 202

  • Zacks

    What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now?

    Does MEREO BIOPHARMA (MREO) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Globe Newswire

    Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference

    LONDON, April 13, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, and other members of Mereo’s management team, will participate in a fireside chat during the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 01:45pm GMT / 08:45am ET. A live audio webcast of the fireside chat can be accesse

  • Globe Newswire

    Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

    LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate highlights. “In 2022, we made important progress in the ongoing advancement of our core rare disease programs. The data from our Phase 2 ASTRAEUS study of alvelestat in severe alpha-1-antitrypsin defic

  • Globe Newswire

    Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

    Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional confirmatory study required Company to host conference call today at 8:30am ET LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases, today announced regulatory feedback following

  • Globe Newswire

    Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

    LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 01:00pm GMT / 08:00am ET. A live audio webcast of the fireside chat can be accessed through the Investors

  • Simply Wall St.

    Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year

    A look at the shareholders of Mereo BioPharma Group plc ( NASDAQ:MREO ) can tell us which group is most powerful. We...

  • Zacks

    MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  • Globe Newswire

    Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

    LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm GMT / 07:55am ET. A live audio webcast of the fireside chat can be accessed through the Investors sectio

  • Globe Newswire

    Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

    LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that on November 1, 2022, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that its American Depositary Shares (“ADSs”) failed to maintain a minimum bid price of $1.00 over the previous 30 consecut

  • Globe Newswire

    Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

    Mereo to Appoint Four New Directors to its Board of Directors Rubric has Withdrawn its General Meeting Requisition Notice and Related Proposals; Agrees to Standstill Provision Through Mereo’s 2024 Annual General Meeting of Shareholders LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced it has entered into a cooperation agreement (the “Agre

  • Globe Newswire

    Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

    LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD). The update will include commentary from and Q&A with leading pulmonary experts, further to the receipt of Fast Track Designation for a

  • Globe Newswire

    Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

    Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s Rejection of Reasonable Settlement Proposals and Refusal to Find a Constructive Solution, Escalating its Costly and Distracting Proxy Campaign at the Expense of All Mereo Shareholders Cautions that Rubric’s Underqualified Nominees Would Threaten Mereo’s Strategic Plan and Risk the Company’s Ability to Brin

  • Business Wire

    Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

    NEW YORK, October 18, 2022--Rubric Capital Management LP ("Rubric"), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), today issued the following statement in response to the Company’s updated operating plan:

  • Globe Newswire

    Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

    Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones Reiterates Commitment to Disciplined Capital Allocation and Management of Mereo’s Promising Pipeline Provides Encouraging Development Updates on Lead Programs; Follows Alvelestat’s Fast Track Designation by the U.S. Food & Drug Administration LONDON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the

  • Globe Newswire

    Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

    Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophi

  • Globe Newswire

    Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

    Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced, Highly Qualified Board and Urges Shareholders to Reject Rubric’s Proposals to Replace a Majority of the Independent Directors at the Upcoming General Meeting LONDON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceuti

  • Business Wire

    Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

    NEW YORK, October 03, 2022--Rubric Capital Management LP ("Rubric"), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), today issued an open letter to Mereo’s shareholders. In its letter, Rubric details Mereo’s entrenching tactics in a desperate attempt to once more thwart Rubric’s effort to call a general meeting of shareholders.

  • Globe Newswire

    Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

    Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements of the Companies Act 2006 Which Apply to All U.K. Companies and Shareholders LONDON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, offered to resolve matters with Rubric Capital Management

  • Business Wire

    Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

    NEW YORK, September 14, 2022--Rubric Capital Management LP ("Rubric"), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), today issued an open letter to Mereo’s shareholders. In its letter, Rubric highlighted Mereo’s poor corporate governance and performance, and addressed the Company’s many misleading public statements regarding Rubric’s attempts to constructively eng

  • Globe Newswire

    Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

    Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination of etigilimab and nivolumab, including in PD-L1 negative or low subjects LONDON and MOUNTAIN VIEW, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on rare diseases and oncology, today reported upd

  • Globe Newswire

    Mereo BioPharma Sends Letter to Rubric Capital Management

    Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions Announces Further Extension of Cash Runway into Q2 2025 LONDON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today sent a letter to Rubric Capital Management LP (“Rubric”) responding to Rubric’s recent public statements regarding Mereo’s